$ARMP
Armata Pharmaceuticals, Inc. Stock $armp

$armp Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000114420415031520 Filed on May 15, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2014 Q1
Revenue	$102.0K	$100.0K	$104.0K
YoY Change	-1.92%	-140.0%	372.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.400M	$1.560M	$1.630M
YoY Change	-14.11%	24.8%	136.23%
% of Gross Profit
Research & Development	$972.0K	$1.110M	$1.011M
YoY Change	-3.86%	-7.5%	83.48%
% of Gross Profit
Depreciation & Amortization	$58.00K	$80.00K	$18.00K
YoY Change	222.22%	700.0%	-25.0%
% of Gross Profit
Operating Expenses	$2.369M	$2.680M	$2.638M
YoY Change	-10.2%	9.39%	113.6%
Operating Profit	-$2.267M		-$2.534M
YoY Change	-10.54%		108.9%
Interest Expense	-$11.80M	$1.930M	$0.00
YoY Change		-37.94%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$431.0K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Pretax Income	-$14.49M	-$660.0K	-$11.31M
YoY Change	28.12%	-253.49%	598.15%
Income Tax
% Of Pretax Income
Net Earnings	-$14.49M	-$660.0K	-$11.31M
YoY Change	28.18%	-253.49%	601.43%
Net Earnings / Revenue	-14208.82%	-660.0%	-10872.12%
Basic Earnings Per Share
Diluted Earnings Per Share	-$483.0M	-$22.00M	-$377.0M
COMMON SHARES
Basic Shares Outstanding		187.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.63M	$6.580M	$16.44M
YoY Change	1.16%	-67.68%
Cash & Equivalents	$16.63M	$6.581M	$16.44M
Short-Term Investments
Other Short-Term Assets	$410.0K	$340.0K	$350.0K
YoY Change	17.14%	13.33%
Inventory
Prepaid Expenses
Receivables	$0.00	$100.0K	$12.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.04M	$7.020M	$16.73M
YoY Change	1.86%	-66.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.197M	$1.220M	$356.0K
YoY Change	236.24%	741.38%
Goodwill	$7.562M	$7.562M	$4.329M
YoY Change	74.68%	0.0%
Intangibles	$12.45M	$12.45M
YoY Change		0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$21.57M	$21.60M	$17.62M
YoY Change	22.37%	5.08%
TOTAL ASSETS
Total Short-Term Assets	$17.04M	$7.020M	$16.73M
Total Long-Term Assets	$21.57M	$21.60M	$17.62M
Total Assets	$38.60M	$28.62M	$34.35M
YoY Change	12.38%	-30.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.550M	$1.170M	$890.0K
YoY Change	74.16%	-45.58%
Accrued Expenses	$430.0K	$460.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.122M	$1.868M	$879.0K
YoY Change	141.41%	-21.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$34.15M	$18.24M	$66.44M
YoY Change	-48.6%	-68.37%
Total Long-Term Liabilities	$34.15M	$18.24M	$57.58M
YoY Change	-40.69%	-64.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.122M	$1.868M	$879.0K
Total Long-Term Liabilities	$34.15M	$18.24M	$57.58M
Total Liabilities	$39.35M	$23.19M	$58.46M
YoY Change	-32.68%	-63.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$376.5M	-$362.0M	-$394.8M
YoY Change	-4.64%	-6.0%
Common Stock	$2.779M	$1.992M	$1.825M
YoY Change	52.27%	9.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.076M	$3.437M	-$24.11M
YoY Change
Total Liabilities & Shareholders Equity	$38.60M	$28.62M	$34.35M
YoY Change	12.38%	-30.56%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2014 Q1
OPERATING ACTIVITIES
Net Income	-$14.49M	-$660.0K	-$11.31M
YoY Change	28.18%	-253.49%	601.43%
Depreciation, Depletion And Amortization	$58.00K	$80.00K	$18.00K
YoY Change	222.22%	700.0%	-25.0%
Cash From Operating Activities	-$2.310M	-$3.200M	-$3.690M
YoY Change	-37.4%	126.95%	229.46%
INVESTING ACTIVITIES
Capital Expenditures	$35.00K	$0.00	$229.0K
YoY Change	-84.72%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$40.00K	$0.00	-$230.0K
YoY Change	-82.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	12.38M	0.000	0.000
YoY Change		-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-2.310M	-3.200M	-3.690M
Cash From Investing Activities	-40.00K	0.000	-230.0K
Cash From Financing Activities	12.38M	0.000	0.000
Net Change In Cash	10.03M	-3.200M	-3.920M
YoY Change	-355.87%	-120.63%	2700.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.310M	-$3.200M	-$3.690M
Capital Expenditures	$35.00K	$0.00	$229.0K
Free Cash Flow	-$2.345M	-$3.200M	-$3.919M
YoY Change	-40.16%	126.95%	249.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	AmpliPhi Biosciences Corp
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000921114
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q1	dei	Trading Symbol TradingSymbol	APHB
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	281623970	shares
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: the determination of the fair value of stock-based awards, the fair value of liability-classified preferred stock derivatives, the fair value of liability-classified warrants, the valuation of long-lived assets, including in-process research and development (IPR&D), patents and goodwill, accrued expenses and the recoverability of the Company's net deferred tax assets and related valuation allowance.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	433000	USD
CY2015Q1	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.14
CY2014Q4	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	0.14
CY2015Q1	us-gaap	Share Price SharePrice	0.30
CY2014Q4	us-gaap	Share Price SharePrice	0.21
CY2015Q1	aphb	Employee Benefit Accured Liabilities EmployeeBenefitAccuredLiabilities	433000	USD
CY2015Q1	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	2328000	USD
CY2014Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	1990000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	2779000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	1992000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	370644000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	457000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2122000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1868000	USD
CY2015Q1	us-gaap	Assets Assets	38604000	USD
CY2014Q4	us-gaap	Assets Assets	28617000	USD
CY2015Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1547000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1167000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	39352000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	23190000	USD
CY2015Q1	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	7105000	USD
CY2015Q1	aphb	Derivative Preferred Shares Conversion Liability DerivativePreferredSharesConversionLiability	19425000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16625000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6581000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	413000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	339000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	17038000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	7020000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1197000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1220000	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12446000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12446000	USD
CY2015Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	361000	USD
CY2014Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	369000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	7562000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	7562000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	363451000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376499000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-362006000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	-3076000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	3437000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38604000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28617000	USD
CY2015Q1	aphb	Derivative Warrants Liability DerivativeWarrantsLiability	14727000	USD
CY2015Q1	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	4690000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22034747	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	39250000	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	63314696	shares
CY2015Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	124599443	shares
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	400000	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M28D
CY2015Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000	shares
CY2015Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8671040	shares
CY2014Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	8671040	shares
CY2015Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	8671040	shares
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	8671040	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	445000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	445000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	277946973	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	199159093	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	277946973	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	199159093	shares
CY2014Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	104000	USD
CY2015Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	102000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1011000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	972000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1627000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1397000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	2638000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	2369000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2534000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2267000	USD
CY2014Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-8773000	USD
CY2015Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-11795000	USD
CY2014Q1	us-gaap	Other Expenses OtherExpenses	0	USD
CY2015Q1	us-gaap	Other Expenses OtherExpenses	431000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-11307000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-14493000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-22625000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	23109000	USD
CY2014	aphb	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1595000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8266000	USD
CY2014	aphb	Stock Issued During Period Value Conversion Of Convertible Securities1 StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1	707000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	775000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52000	USD
CY2014	aphb	Stock Issued During Period Value Shares Released From Escrow StockIssuedDuringPeriodValueSharesReleasedFromEscrow	0	USD
CY2014	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1161000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000	USD
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	213000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	18000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	58000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	234000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	52000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-100000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1365000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	158000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-122000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	48000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	74000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3691000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2305000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	229000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	35000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-229000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-35000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12384000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3920000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10044000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20355000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16435000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11621000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14831000	USD
CY2015Q1	aphb	Employee Related Liabilities Noncurrent EmployeeRelatedLiabilitiesNoncurrent	0	USD
CY2014Q4	aphb	Employee Related Liabilities Noncurrent EmployeeRelatedLiabilitiesNoncurrent	98000	USD
CY2015Q1	aphb	Preffered B Stock Conversion Liability PrefferedBStockConversionLiability	19425000	USD
CY2014Q4	aphb	Preffered B Stock Conversion Liability PrefferedBStockConversionLiability	12320000	USD
CY2015Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	14727000	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5826000	USD
CY2014Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	314000	USD
CY2015Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	338000	USD
CY2014	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-1285000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	234000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52000	USD
CY2014Q1	aphb	Warrant Exercised WarrantExercised	0	USD
CY2015Q1	aphb	Warrant Exercised WarrantExercised	4211000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	244000	USD
CY2015Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3078000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3078000	USD
CY2015Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	14380000	USD
CY2014Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	14042000	USD
CY2014Q1	aphb	Proceeds From March Financing Activities ProceedsFromMarchFinancingActivities	0	USD
CY2015Q1	aphb	Proceeds From March Financing Activities ProceedsFromMarchFinancingActivities	12384000	USD
CY2014	us-gaap	Severance Costs1 SeveranceCosts1	1864000	USD
CY2015Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.96	pure
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0036	pure
CY2015Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0026	pure
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0	pure
CY2015Q1	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0	pure
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	132692650	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	99493212	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	13000000	USD
CY2015Q1	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1.40
CY2015Q1	aphb	Payments For Severance Costs PaymentsForSeveranceCosts	-122000	USD
CY2015Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	34152000	USD
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	18146000	USD
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.91	pure
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y3M
CY2015Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8773000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12226000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	182535562	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	212290406	shares
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2400000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.18
CY2014Q4	aphb	Employee Benefit Accured Liabilities EmployeeBenefitAccuredLiabilities	555000	USD
CY2015Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	4211000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3998000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	218000	USD
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.30
CY2015Q1	aphb	Fees Paid To Placement Agent FeesPaidToPlacementAgent	833000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	19696971	shares
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.215
CY2015Q1	aphb	Warrant Liquidation Charges WarrantLiquidationCharges	2.5	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	4727273	shares
CY2015Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4211000	USD
CY2013	aphb	Warrant Expiration Date WarrantExpirationDate	December 2018
CY2015Q1	aphb	Warrant Expiration Date WarrantExpirationDate	March 2020
CY2014Q1	aphb	Convertible Preferred Stock Accretion To Redemption Value Adjustment ConvertiblePreferredStockAccretionToRedemptionValueAdjustment	314000	USD
CY2015Q1	aphb	Convertible Preferred Stock Accretion To Redemption Value Adjustment ConvertiblePreferredStockAccretionToRedemptionValueAdjustment	338000	USD

Files In Submission

Name	View Source	Status
0001144204-15-031520-index-headers.html	Edgar Link	pending
0001144204-15-031520-index.html	Edgar Link	pending
0001144204-15-031520.txt	Edgar Link	pending
0001144204-15-031520-xbrl.zip	Edgar Link	pending
aphb-20150331.xml	Edgar Link	completed
aphb-20150331.xsd	Edgar Link	pending
aphb-20150331_cal.xml	Edgar Link	unprocessable
aphb-20150331_def.xml	Edgar Link	unprocessable
aphb-20150331_lab.xml	Edgar Link	unprocessable
aphb-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v410338_10q.htm	Edgar Link	pending
v410338_ex31-1.htm	Edgar Link	pending
v410338_ex31-2.htm	Edgar Link	pending
v410338_ex32-1.htm	Edgar Link	pending
v410338_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARMP
Armata Pharmaceuticals, Inc. Stock $armp

2015 Q1 Form 10-Q Financial Statement

#000114420415031520 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARMP Armata Pharmaceuticals, Inc. Stock $armp

2015 Q1 Form 10-Q Financial Statement

#000114420415031520 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARMP
Armata Pharmaceuticals, Inc. Stock $armp